A 28-year-old woman on combined oral contraceptives (COCs) with ethinylestradiol 30 µg and levonorgestrel presents with breakthrough bleeding. Which pharmacological property of the progestin component best distinguishes levonorgestrel-containing COCs from those containing desogestrel or gestodene?

Explanation

## Distinguishing Progestin Properties: Levonorgestrel vs. Modern Progestins ### Levonorgestrel (First-Generation Progestin) **Key Point:** Levonorgestrel is a 19-nortestosterone derivative with significant androgenic activity. It: - Binds androgen receptors with measurable affinity - Provides less endometrial suppression relative to its progestational potency - May cause breakthrough bleeding due to inadequate endometrial stability - Has metabolic effects (lipid changes, glucose effects) ### Modern Progestins (Desogestrel, Gestodene) **Key Point:** These are newer 19-nortestosterone derivatives engineered to: - Minimize androgenic activity (lower androgen receptor binding) - Maximize progestational selectivity - Provide superior endometrial suppression - Reduce breakthrough bleeding rates - Have fewer metabolic side effects ### Comparison Table | Property | Levonorgestrel | Desogestrel/Gestodene | | --- | --- | --- | | **Androgenic activity** | Moderate to high | Minimal | | **Endometrial suppression** | Adequate but lower | Superior | | **Breakthrough bleeding** | Higher incidence | Lower incidence | | **Androgen receptor binding** | Significant | Negligible | | **Metabolic effects** | Lipid ↑, glucose effects | Minimal | | **Progestational selectivity** | Lower | Higher | **High-Yield:** The breakthrough bleeding in this patient likely reflects levonorgestrel's relatively poor endometrial suppression despite adequate progestational activity. Modern progestins suppress the endometrium more effectively, reducing breakthrough bleeding. **Mnemonic:** **LAND** = **L**evonorgestrel = **A**ndrogenic, **N**eed more endometrial support, **D**ifferent from newer progestins. **Clinical Pearl:** Breakthrough bleeding on levonorgestrel-containing COCs is a classic indication to switch to a second- or third-generation progestin (desogestrel, gestodene, or norgestimate) to improve endometrial stability. [cite:KD Tripathi 8e Ch 62]